RESUMO
Objetivos. Evaluar la duración en el tiempo de la disminución de los volúmenes del fibroma, el útero y la sintomatología en mujeres tratadas con mifepristona. Pacientes y métodos. 100 mujeres con fibromatosis uterina sintomática aleatorizadas a recibir 10 o 5mg de mifepristona fueron seguidas por 6 meses postratamiento. Resultados. Seis meses después del tratamiento el tamaño del fibroma fue 19%, un 23% menor que el valor inicial en los grupos de 10 y 5mg de mifepristona, respectivamente, y el volumen del útero fue del 8%, un 17% menor que al inicio en los grupos de 10 y 5mg, respectivamente. La prevalencia de síntomas se mantenía significativamente menor que antes del tratamiento. Conclusiones. Seis meses después de concluido el tratamiento, los tamaños del fibroma y del útero presentan valores cercanos a los iniciales pretratamiento, pero persistía aun una notable mejoría clínica (AU)
Objectives. To evaluate the extent in time of the reduction of uterine and fibroids size in women treated with mifepristone. Patients and methods. One-hundred women who received mifepristone 10 or 5mg for three months were followed-up for six months after treatment termination. Results. Six months after treatment the fibroids mean sizes were 19% and 23% lower than baseline values in 10 and 5mg mifepristone groups, respectively, and mean uterine volumes were 8% and 17% lesser than before treatment in 10 and 5mg groups, respectively. Prevalence of symptoms was still significantly lower than before treatment. Conclusions. Six months after treatment termination the sizes of fibroids and uteri were near to the initial values but a clinical improvement was maintained (AU)
Assuntos
Humanos , Feminino , Adulto , Leiomioma/complicações , Leiomioma/tratamento farmacológico , Mifepristona/uso terapêutico , Leiomioma/diagnóstico , Metrorragia/complicações , Fibroma/tratamento farmacológico , Abdome , Histerectomia/métodosRESUMO
OBJECTIVE: To estimate the efficacy of daily administration of 5 mg compared with 10 mg of mifepristone for the treatment of uterine myomas. METHODS: One hundred women were randomly assigned to receive oral mifepristone 5 mg or 10 mg daily for 3 months (50 per group). Abdominal ultrasonography was performed before treatment, at 45 days, and at 3 months to evaluate leiomyoma and uterine volumes. Endometrial biopsy specimens were taken before and after treatment. Efficacy was estimated by the reduction percentages of the leiomyoma and uterine volumes. RESULTS: After 90 days treatment there was a 45% (95% confidence interval [CI] 37-54, P<.001) and a 57% (95% CI 48-67, P<.001) reduction in the leiomyoma volume in the 10-mg and 5-mg groups, respectively, and one of 40% (95% CI 34-46, P=.002), and 36% (95% CI 31-40, P<.001), respectively, in the uterine volume. Symptomatic improvement was noted, and the prevalence of symptoms diminished significantly. There were no significant differences in reduction of volume and symptoms in the treatment groups, P>.05 in all cases. After treatment, 44 of 49 (89.8%) women from the mifepristone 10 mg group and 45 of 50 (90.0%) from the 5-mg group, respectively, were amenorrheic (P=.487). Endometrial biopsy after treatment showed simple hyperplasia in 1 of 50 (2.0%) in the mifepristone 10 mg group. CONCLUSION: Five-milligram doses of mifepristone produce reductions in leiomyoma and uterine volumes and symptomatic improvement similar to 10-mg doses. LEVEL OF EVIDENCE: I.
